# KunJin Phase 3 Independent Financial And Product Review

## Decision

Phase 3 delivers a materially clearer portfolio-diagnosis workflow, but it does
not make KunJin a complete fund-selection or trading adviser. The implementation
is useful for answering "what is visibly concentrated or duplicated in my
current portfolio?" and for checking one user-supplied candidate against that
observed evidence. It cannot support a 90% beginner-help claim.

The main improvement is product usability and epistemic discipline: one command
now combines existing portfolio, relationship, and disclosed-holdings engines,
labels coverage, keeps unknown evidence unknown, and refuses to authorize an
action or amount. It does not improve the underlying freshness or breadth of the
fund disclosures already stored locally.

## Verification Evidence

Fresh Phase 3 acceptance produced:

- complete repository regression: 2794 passed;
- local diagnosis acceptance: 126 passed, with no process residue;
- fault and degradation acceptance: 20 passed, with no process residue;
- Phase 3 smoke contracts: 2 passed;
- Ruff, Bash syntax, Skill validation, and `git diff --check`: passed; and
- owner acceptance: passed against a SQLite read-only backup and emitted only
  anonymous counts, coverage states, stable gap categories, and booleans.

The owner result covered 10 positions. Relationship coverage was `partial`,
holdings coverage was `insufficient_data`, one relationship and three findings
were emitted, and the command returned structured `insufficient_data`. No fund
code, amount, weight, cost, profit, shares, account title, or profile value was
printed. No child process remained after the run.

## Independent Financial Assessment

Scores reflect current real evidence, not ideal behavior with every source and
disclosure available.

| Beginner workflow | Score | Evidence-based assessment |
| --- | ---: | --- |
| Recent news | 6/10 | Unchanged by Phase 3. Dated bounded news remains useful, but source breadth and the prior partial STCN result remain limitations. |
| Market direction or what to buy | 2/10 | Unchanged. Portfolio structure does not establish valuation, market regime, or a suitable buying direction. |
| Named candidate fund | 4/10 | Improved by one-candidate observed-duplication checks, but current market relevance, full product comparison, suitability, fees/channel checks, and purchase authorization remain incomplete. |
| Daily hold or sell review | 1/10 | Unchanged. Phase 3 does not add new-event monitoring, thesis invalidation evidence, or a reliable sell-timing process. |
| Portfolio duplication and risk | 6/10 | The single diagnosis command is clearer and safer, but the real owner run had partial relationship coverage and insufficient holdings coverage, so important duplication can still be unknown. |

Overall current real-world usefulness remains approximately 4/10. Phase 3
improves the fifth workflow and part of the third; it does not materially repair
the other three. A healthy-data capability score would be higher, but that
hypothetical score must not replace the observed owner result.

## What Phase 3 Now Supports

- current-position count and concentration only when the local value basis is
  usable;
- authenticated same-manager, exact benchmark-text, and sibling share-class
  relationships already supported by the existing D2 engine;
- observed top-ten disclosed security or industry duplication with report and
  publication dates;
- explicit included, omitted, and unknown fund coverage;
- one user-supplied candidate's observed duplication or distinct disclosed
  exposure; and
- deterministic local diagnosis with no network refresh, automatic trade,
  action authorization, or exact amount.

## Remaining Material Gaps

- Phase 2's real Eastmoney market-source failure is not fixed by Phase 3.
- Phase 2's owner brief core-evidence failure is not fixed by Phase 3.
- Missing or stale quarterly holdings still prevent a reliable whole-portfolio
  overlap conclusion; top-ten disclosure is not full look-through.
- Benchmark text equality is not authenticated index identity, and the current
  industry taxonomy is not complete.
- Correlation, stress testing, valuation, candidate quality ranking, share-class
  and channel authorization, and candidate marginal amount remain deferred.
- A candidate label describes observed evidence only. It is not "recommended",
  "safe", "diversified", or suitable to buy.
- Holding, reduction, exit, and exact-amount gates remain unavailable.

## Next Phase Boundary

Phase 4 should focus on a bounded two-to-five-candidate comparison and
pre-purchase evidence check using user-supplied candidates. It should not add
per-fund website adapters, automatic candidate discovery, exact amounts, or a
universal score. Current market and fee/share-class gaps must remain explicit
abstention reasons rather than being filled by inference.
